Here are four things to know:
1. Participants will undergo white blood cell collection via a leukapheresis procedure. These cells will be modified to attack cancer; after modification, these cells are called “CAR-T cells.”
2. After two to three weeks, the cells are returned to the patient, at which point they will receive three CAR-T infusions delivered directly into the liver once a week for a duration of 10 weeks.
3. Low dose interleukin-2, a protein produced by T-cells, will be delivered by a portable pump during the T-cell infusion period.
4. At the end of the 10-week period, a final imaging test is performed.
More articles on gastroenterology and endoscopy:
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis
ASGE comments on 21st Century Cures Act: 3 notes
IBD monitoring index may pave the way for GI mobile health: 3 study insights
